1
|
Alibaz-Öner F, Kelesoglu B, Balci MA, Yardimci GK, Armağan B, Kiliç L, Karakaş Ö, Erden A, Yasar Bilge S, Kardaş RC, Küçük H, Zengin O, Tasci M, Kocaer SB, Yavuz S, Dogru A, Şahin M, Bayindir O, Sevik G, Ertürk Z, Alpay-Kanitez N, Gogebakan H, Tezcan ME, Oksuz MF, Cefle A, Kucuksahin O, Yazici A, Kasapoglu E, Bes C, Unal AU, Dalkiliç E, Yildirim Çetin G, Aksu K, Keser G, Onen F, Çobankara V, Kisacik B, Onat AM, Öztürk MA, Kaşifoğlu T, Omma A, Karadag O, Ates A, Direskeneli H. Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry. Clin Exp Rheumatol 2024; 42:816-821. [PMID: 37976117 DOI: 10.55563/clinexprheumatol/zr7s0g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 09/21/2023] [Indexed: 11/19/2023]
Abstract
OBJECTIVES Glucocorticoids (GC) are widely accepted as the standard first-line treatment for giant cell arteritis (GCA). However, relapse rates are reported up to 80% on GC-only protocol arms in controlled trials of tocilizumab and abatacept in 12-24 months. Herein, we aimed to assess the real-life relapse rates retrospectively in patients with GCA from Turkey. METHODS We assembled a retrospective cohort of patients with GCA diagnosed according to ACR 1990 criteria from tertiary rheumatology centres in Turkey. All clinical data were abstracted from medical records. Relapse was defined as any new manifestation or increased acutephase response leading to the change of the GC dose or use of a new therapeutic agent by the treating physician. RESULTS The study included 330 (F/M: 196/134) patients with GCA. The mean age at disease onset was 68.9±9 years. The most frequent symptom was headache. Polymyalgia rheumatica was also present in 81 (24.5%) patients. Elevation of acute phase reactants (ESR>50 mm/h or CRP>5 mg/l) was absent in 25 (7.6%) patients at diagnosis. Temporal artery biopsy was available in 241 (73%) patients, and 180 of them had positive histopathological findings for GCA. For remission induction, GC pulses (250-1000 methylprednisolone mg/3-7 days) were given to 69 (20.9%) patients, with further 0.5-1 mg/kg/day prednisolone continued in the whole group. Immunosuppressives as GC-sparing agents were used in 252 (76.4%) patients. During a follow-up of a median 26.5 (6-190) months, relapses occurred in 49 (18.8%) patients. No confounding factor was observed in relapse rates. GC treatment could be stopped in only 62 (23.8%) patients. Additionally, GC-related side effects developed in 64 (24.6%) patients, and 141 (66.2%) had at least one Vasculitis Damage Index (VDI) damage item present during follow-up. CONCLUSIONS In this first multi-centre series of GCA from Turkey, we observed that only one-fifth of patients had relapses during a mean follow-up of 26 months, with 76.4% given a GC-sparing IS agent at diagnosis. At the end of follow-up, GC-related side effects developed in one-fourth of patients. Our results suggest that patients with GCA had a low relapse rate in real-life experience of a multi-centre retrospective Turkish registry, however with a significant presence of GC-associated side effects during follow-up.
Collapse
Affiliation(s)
- Fatma Alibaz-Öner
- Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey.
| | - Bahar Kelesoglu
- Ankara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Mehmet Ali Balci
- Istanbul Physical Medicine and Rehabilitation Training and Research Hospital, University of Health Sciences, Clinic of Rheumatology, Istanbul, Turkey
| | - Gözde Kübra Yardimci
- Hacettepe University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Berkan Armağan
- Hacettepe University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara; and Health Sciences University, Ministry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara, Turkey
| | - Levent Kiliç
- Hacettepe University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Özlem Karakaş
- Health Sciences University, Ministry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara, Turkey
| | - Abdulsamet Erden
- Health Sciences University, Ministry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara, Turkey
| | - Sule Yasar Bilge
- Eskisehir Osmangazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir, Turkey
| | - Riza Can Kardaş
- Gazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Hamit Küçük
- Gazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Orhan Zengin
- Gaziantep University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Gaziantep, Turkey
| | - Murat Tasci
- Abant Izzet Baysal University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Bolu, Turkey
| | - Sinem Burcu Kocaer
- Dokuz Eylul University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
| | - Sule Yavuz
- Bilim University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
| | - Atalay Dogru
- Süleyman Demirel University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey
| | - Mehmet Şahin
- Süleyman Demirel University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey
| | - Ozun Bayindir
- Ege University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
| | - Gizem Sevik
- Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
| | - Zeynep Ertürk
- Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, and Medipol University, Çamlica Hospital, Clinic of Rheumatology, Istanbul, Turkey
| | - Nilüfer Alpay-Kanitez
- Koç University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
| | - Hasan Gogebakan
- Kahramanmaras Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey
| | - Mehmet Engin Tezcan
- Kartal Dr. Lutfi Kirdar City Hospital, Clinic of Rheumatology, Istanbul, Turkey
| | - Mustafa Ferhat Oksuz
- Uludag University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, and Medical Park Pendik Hospital, Clinic of Rheumatology, Istanbul, Turkey
| | - Ayse Cefle
- Kocaeli University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kocaeli, Turkey
| | - Orhan Kucuksahin
- Medeniyet University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
| | - Ayten Yazici
- Kocaeli University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kocaeli, Turkey
| | - Esen Kasapoglu
- Medeniyet University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
| | - Cemal Bes
- Basaksehir Cam and Sakura City Hospital, University of Health Sciences Department of Rheumatology, Istanbul, Turkey
| | - Ali Ugur Unal
- Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, and Medical Park Ordu Hospital, Clinic of Rheumatology, Ordu, Turkey
| | - Ediz Dalkiliç
- Uludag University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey
| | - Gözde Yildirim Çetin
- Kahramanmaras Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey
| | - Kenan Aksu
- Ege University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
| | - Gökhan Keser
- Ege University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
| | - Fatos Onen
- Dokuz Eylul University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
| | - Veli Çobankara
- Pamukkale University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Denizli, Turkey
| | - Bünyamin Kisacik
- Sanko University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Gaziantep, Turkey
| | - Ahmet Mesut Onat
- Medical Park Gaziantep Hospital, Clinic of Rheumatology, Gaziantep, Turkey
| | - Mehmet Akif Öztürk
- Gazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Timuçin Kaşifoğlu
- Eskisehir Osmangazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir, Turkey
| | - Ahmet Omma
- Health Sciences University, Ministry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara, Turkey
| | - Omer Karadag
- Hacettepe University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Askin Ates
- Ankara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
| | - Haner Direskeneli
- Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
| |
Collapse
|
2
|
Ersozlu ED, Bakirci S, Sunu C, Ertürk Z, Açıkgöz SB, Tamer A. Use of nailfold video capillaroscopy in polycythemia vera. Arch Rheumatol 2021; 37:404-410. [PMID: 36589600 PMCID: PMC9791553 DOI: 10.46497/archrheumatol.2022.9271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Accepted: 10/28/2021] [Indexed: 01/04/2023] Open
Abstract
Objectives In this study, we aimed to investigate capillary vessel diameters and structural changes of capillaries by using nailfold video capillaroscopy (NVC) in patients with polycythemia vera (PV). Patients and methods This cross-sectional study included a total of 24 patients (19 males, 5 females; mean age: 59.8±12.9 years; range, 50.2 to 68 years) who were diagnosed with PV and 15 healthy controls (11 males, 4 females; mean age: 40.7±5.1 years; range, 36 to 44 years) between June 2016 and February 2017. Nailfold video capillaroscopy was performed by an experienced rheumatologist who was blinded to clinical data. The apical, arterial, and venous limb diameters of capillaries were measured and microvascular changes of capillaries were scored. Results When capillaries were evaluated in terms of morphological structures, giant capillary was detected in 67% of the patients with PV and 0% in the control group (p<0.05). The arterial, venous, and apical diameters of the capillaries were significantly higher in the patients with PV compared to the control group (p<0.001). Conclusion The presence of giant capillaries and the marked increase of arterial, venous, and apical diameters of capillaries seem to be related to PV. As it additionally plays an important role in diagnosis, prognosis, and treatment monitoring of certain diseases, capillaroscopy can be considered to be a promising microcirculation biomarker.
Collapse
Affiliation(s)
| | - Sibel Bakirci
- Antalya Training and Research Hospital, Rheumatology, Antalya, Turkey
| | - Cenk Sunu
- Sakarya Training and Research Hospital, Hematology, Sakarya, Turkey
| | - Zeynep Ertürk
- Sakarya Training and Research Hospital, Internal Medicine, Sakarya, Turkey
| | | | - Ali Tamer
- Sakarya Training and Research Hospital, Internal Medicine, Sakarya, Turkey
| |
Collapse
|
3
|
Inanc N, Şahinkaya Y, Mumcu G, Türe Özdemir F, Paksoy A, Ertürk Z, Direskeneli H, Bruyn GA. Evaluation of salivary gland ultrasonography in primary Sjögren's syndrome: does it reflect clinical activity and outcome of the disease? Clin Exp Rheumatol 2019; 37 Suppl 118:140-145. [PMID: 31287407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Accepted: 04/29/2019] [Indexed: 06/09/2023]
Abstract
OBJECTIVES To evaluate associations between salivary gland ultrasonography (SGUS) and clinical characteristics, disease activity and outcome in patients with primary Sjögren's syndrome (pSS). METHODS The parotid and submandibular salivary glands were examined by ultrasonography using two different scoring systems proposed by Hocevar et al. and Milic et al. on 85 pSS patients. Patients with inhomogeneity/hypoechoic areas with scores ≥2 in parotid and submandibular glands were classified as severe parotid or severe submandibular involvements, respectively. Disease activity and patient-reported severity were evaluated using the European League Against Rheumatism Sjögren's Disease Activity Index (ESSDAI) and the European League Against Rheumatism Sjögren's Patient Reported Index (ESSPRI). Salivary gland functional capacity was investigated by unstimulated whole saliva flow rate (U-WSFR). RESULTS Of the activity scores, ESSPRI dryness component was higher in pSS patients who had scores above the cut-off values for Hocevar (6.1±2.3 vs. 4.9±2.6, p=0.026). The patients with any type of systemic involvement more frequently showed higher SGUS scores, according to both Hocevar (72.4 vs. 44.6%, p=0.013) and Milic (75.9 vs. 51.8%, p=0.026). These patients also showed a higher percentage of severe parotid/submandibular changes on US imaging (65.5 vs. 33.9%, p=0.005 and 75.9 vs. 51.8%, p=0.026 respectively). Higher SGUS scores according to cut-off values of both scoring systems and severe parotid/submandibular involvements were associated with both anti-Ro or double anti-Ro/La autoantibodies and inversely associated with U-WSFR. CONCLUSIONS SGUS may be a useful imaging modality for the selection of patients with more severe disease status or who may require a tight follow-up schedule.
Collapse
Affiliation(s)
- Nevsun Inanc
- Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey.
| | - Yasemin Şahinkaya
- Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
| | - Gonca Mumcu
- Department of Health Management, Marmara University Faculty of Health Sciences, Istanbul, Turkey
| | - Filiz Türe Özdemir
- Division of Immunology, Marmara University, School of Medicine, Istanbul, Turkey
| | | | - Zeynep Ertürk
- Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
| | - Haner Direskeneli
- Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
| | - George A Bruyn
- Department of Rheumatology, MC Groep Hospitals, Leystad, The Netherlands
| |
Collapse
|